HSINCHU, Taiwan, Oct. 20, 2015 /PRNewswire/ -- JHL Biotech (TWEM: 6540), an emerging biosimilars company in Taiwan and China, announced today that Max Chan will join the company as Chief Financial Officer effective today. Other leaders who have recently joined the company include Charles Winter, Vice President of Manufacturing and Technology, and Andreas Nechansky, Vice President of Research and Analytical Operations. Nick Kotlarski was recently promoted to Vice President of Corporate Engineering.
Max Chan joins JHL Biotech as Chief Financial Officer. He will also oversee business development, public relations, and investor relations. Mr. Chan joins JHL Biotech from TaiGen Biopharmaceuticals, where during his five-year tenure as Chief Financial Officer he facilitated the company's initial public offering in Taiwan.
Charles Winter joined JHL Biotech in July as Vice President of Manufacturing and Technology. Mr. Winter previously worked in biologics development at Gilead Sciences. Andreas Nechansky joined JHL Biotech in September as Vice President of Research and Analytical Operations. Dr. Nechansky comes to JHL from Vela Labs, which he co-founded and served as chief operating officer and head of analytical operations. Nick Kotlarski was promoted in September to Vice President of Corporate Engineering. Dr. Kotlarski joined JHL in 2013 from Synertec Asia, a life sciences consultancy in Southeast Asia.
About JHL Biotech
JHL Biotech is an emerging biopharmaceuticals company founded by a group of biotech veterans with decades of manufacturing experience. JHL Biotech has been backed by a consortium of top-tier venture capital firms including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital and China Development Industrial Bank (CDIB). JHL Biotech's mission is to provide affordable world-class medicines to more patients worldwide. JHL Biotech concentrates on developing new protein drugs and biosimilars that comply with international standards. JHL Biotech has capability on cell line development, cell culture, purification, formulation, stability test and GMP manufacturing. In addition to in-house research and development, JHL Biotech has signed co-development agreements with four international medical companies.
JHL Biotech has state-of-the-art facilities built in compliance with United States, European Union and International Conference on Harmonisation (ICH) current good manufacturing practices (cGMP) regulations and guidelines. The company has facilities in Taiwan that support all pre-clinical and early clinical activities for biologics development. JHL is currently building facilities to support commercial manufacturing in Wuhan, China, with an expected completion within two years. With this comprehensive infrastructure in place, JHL Biotech is uniquely positioned to deliver manufacturing solutions to its worldwide partners. For more information about the company, visit www.jhlbiotech.com.
SOURCE JHL Biotech